Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 682

1.

Making the GRADE in Anaphylaxis Management: Towards Recommendations Integrating Values, Preferences, Context, and Shared Decision-Making.

Shaker MS, Oppenheimer J, Wallace DV, Golden DBK, Lang DM; Joint Task Force for Allergy Practice Parameters, Lang ES, Bernstein JA, Campbell RL, Chu D, Dinakar C, Ellis AK, Greenhawt M, Horner C, Lieberman JA, Rank MA, Stukus DR, Wang J.

Ann Allergy Asthma Immunol. 2020 Mar 18. pii: S1081-1206(20)30153-8. doi: 10.1016/j.anai.2020.03.009. [Epub ahead of print]

PMID:
32199979
2.

Medicine and the Mind.

Lieberman JA, Dosovitz SM.

N Engl J Med. 2020 Feb 27;382(9):879. doi: 10.1056/NEJMc1916446. No abstract available.

PMID:
32101680
3.

Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients.

Kantrowitz JT, Javitt DC, Freedman R, Sehatpour P, Kegeles LS, Carlson M, Sobeih T, Wall MM, Choo TH, Vail B, Grinband J, Lieberman JA.

Neuropsychopharmacology. 2020 Feb 3. doi: 10.1038/s41386-020-0628-9. [Epub ahead of print]

PMID:
32015461
4.

Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis.

Shaker MS, Wallace DV, Golden DBK, Oppenheimer J, Bernstein JA, Campbell RL, Dinakar C, Ellis A, Greenhawt M, Khan DA, Lang DM, Lang ES, Lieberman JA, Portnoy J, Rank MA, Stukus DR, Wang J; Collaborators, Riblet N, Bobrownicki AMP, Bontrager T, Dusin J, Foley J, Frederick B, Fregene E, Hellerstedt S, Hassan F, Hess K, Horner C, Huntington K, Kasireddy P, Keeler D, Kim B, Lieberman P, Lindhorst E, McEnany F, Milbank J, Murphy H, Pando O, Patel AK, Ratliff N, Rhodes R, Robertson K, Scott H, Snell A, Sullivan R, Trivedi V, Wickham A; Chief Editors, Shaker MS, Wallace DV; Workgroup Contributors, Shaker MS, Wallace DV, Bernstein JA, Campbell RL, Dinakar C, Ellis A, Golden DBK, Greenhawt M, Lieberman JA, Rank MA, Stukus DR, Wang J; Joint Task Force on Practice Parameters Reviewers, Shaker MS, Wallace DV, Golden DBK, Bernstein JA, Dinakar C, Ellis A, Greenhawt M, Horner C, Khan DA, Lieberman JA, Oppenheimer J, Rank MA, Shaker MS, Stukus DR, Wang J.

J Allergy Clin Immunol. 2020 Jan 28. pii: S0091-6749(20)30105-6. doi: 10.1016/j.jaci.2020.01.017. [Epub ahead of print]

PMID:
32001253
5.

Adjunctive sapropterin dihydrochloride treatment in schizophrenia: A positive proof-of-concept, rater-blind, randomized, multivitamin-controlled study.

Clelland CL, Kantrowitz JT, Choo T, Clelland JD, Lieberman JA.

Schizophr Res. 2020 Jan 21. pii: S0920-9964(19)30609-7. doi: 10.1016/j.schres.2019.12.039. [Epub ahead of print] No abstract available.

PMID:
31973997
6.

Letter to the Editor. Incorrect analysis of motor evoked potential efficacy for pedicle subtraction osteotomy.

Fournier S, Clark JP, Lieberman JA.

J Neurosurg Spine. 2020 Jan 10:1-2. doi: 10.3171/2019.8.SPINE19909. [Epub ahead of print] No abstract available.

PMID:
31923891
7.

Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial.

Correll CU, Davis RE, Weingart M, Saillard J, O'Gorman C, Kane JM, Lieberman JA, Tamminga CA, Mates S, Vanover KE.

JAMA Psychiatry. 2020 Jan 8. doi: 10.1001/jamapsychiatry.2019.4379. [Epub ahead of print] Erratum in: JAMA Psychiatry. 2020 Feb 19;:.

8.

The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures.

Kraus MS, Gold JM, Barch DM, Walker TM, Chun CA, Buchanan RW, Csernansky JG, Goff DC, Green MF, Jarskog LF, Javitt DC, Kimhy D, Lieberman JA, McEvoy JP, Mesholam-Gately RI, Seidman LJ, Ball MP, Kern RS, McMahon RP, Robinson J, Marder SR, Keefe RSE.

Schizophr Res Cogn. 2019 Oct 31;19:100161. doi: 10.1016/j.scog.2019.100161. eCollection 2020 Mar.

9.

Hippocampal Pathology in Clinical High-Risk Patients and the Onset of Schizophrenia.

Provenzano FA, Guo J, Wall MM, Feng X, Sigmon HC, Brucato G, First MB, Rothman DL, Girgis RR, Lieberman JA, Small SA.

Biol Psychiatry. 2020 Feb 1;87(3):234-242. doi: 10.1016/j.biopsych.2019.09.022. Epub 2019 Oct 3.

PMID:
31771861
10.

Clinically relevant immunology for practitioner.

Lieberman JA.

Ann Allergy Asthma Immunol. 2019 Nov;123(5):422-423. doi: 10.1016/j.anai.2019.08.461. No abstract available.

PMID:
31676019
11.

Recency and intensification of positive symptoms enhance prediction of conversion to syndromal psychosis in clinical high-risk patients.

Brucato G, First MB, Dishy GA, Samuel SS, Xu Q, Wall MM, Small SA, Masucci MD, Lieberman JA, Girgis RR.

Psychol Med. 2019 Oct 29:1-9. doi: 10.1017/S0033291719003040. [Epub ahead of print]

PMID:
31658912
12.

Early Detection and Preventive Intervention in Schizophrenia: From Fantasy to Reality.

Lieberman JA, Small SA, Girgis RR.

Am J Psychiatry. 2019 Oct 1;176(10):794-810. doi: 10.1176/appi.ajp.2019.19080865. Review.

PMID:
31569988
13.

The smartest person in the room: Donald F. Klein, M.D. (1928-2019).

Lieberman JA, Fyer A.

Neuropsychopharmacology. 2019 Dec;44(13):2296-2297. doi: 10.1038/s41386-019-0525-2. Epub 2019 Sep 24. No abstract available.

PMID:
31551481
14.

An imaging-based risk calculator for prediction of conversion to psychosis in clinical high-risk individuals using glutamate 1H MRS.

Kegeles LS, Ciarleglio A, León-Ortiz P, Reyes-Madrigal F, Lieberman JA, Brucato G, Girgis RR, de la Fuente-Sandoval C.

Schizophr Res. 2019 Sep 12. pii: S0920-9964(19)30413-X. doi: 10.1016/j.schres.2019.09.004. [Epub ahead of print]

PMID:
31522867
15.

Practical peanut challenges for the clinician.

Lieberman JA.

Allergy Asthma Proc. 2019 Sep 1;40(5):295-300. doi: 10.2500/aap.2019.40.4235.

PMID:
31514788
16.

Long-Term Carriage of Medicopsis romeroi, an Agent of Black-Grain Mycetoma, Presenting as Phaeohyphomycosis in a Renal Transplant Patient.

Lieberman JA, Fiorito J, Ichikawa D, Fang FC, Rakita RM, Bourassa L.

Mycopathologia. 2019 Oct;184(5):671-676. doi: 10.1007/s11046-019-00379-y. Epub 2019 Sep 9.

PMID:
31502092
17.

Identification and Management of Cardiometabolic Risk after Spinal Cord Injury.

Nash MS, Groah SL, Gater DR, Dyson-Hudson TA, Lieberman JA, Myers J, Sabharwal S, Taylor AJ.

J Spinal Cord Med. 2019 Sep;42(5):643-677. doi: 10.1080/10790268.2018.1511401. Epub 2019 Jun 10. No abstract available.

PMID:
31180274
18.

Minimally symptomatic patients with eosinophilic esophagitis should still be actively treated-CON.

Lieberman JA.

Ann Allergy Asthma Immunol. 2019 Jun;122(6):574-575. doi: 10.1016/j.anai.2018.11.020. No abstract available.

PMID:
31171239
19.

New insights into tardive dyskinesia genetics: Implementation of whole-exome sequencing approach.

Alkelai A, Greenbaum L, Heinzen EL, Baugh EH, Teitelbaum A, Zhu X, Strous RD, Tatarskyy P, Zai CC, Tiwari AK, Tampakeras M, Freeman N, Müller DJ, Voineskos AN, Lieberman JA, Delaney SL, Meltzer HY, Remington G, Kennedy JL, Pulver AE, Peabody EP, Levy DL, Lerer B.

Prog Neuropsychopharmacol Biol Psychiatry. 2019 Aug 30;94:109659. doi: 10.1016/j.pnpbp.2019.109659. Epub 2019 May 30.

PMID:
31153890
20.

Richard Resnick.

Lieberman JA.

Neuropsychopharmacology. 2019 Aug;44(9):1674. doi: 10.1038/s41386-019-0419-3. Epub 2019 May 30. No abstract available.

PMID:
31147599
21.

Amygdalar volume and violent ideation in a sample at clinical high-risk for psychosis.

Feng X, Provenzano F, Appelbaum PS, Masucci MD, Brucato G, Lieberman JA, Girgis RR.

Psychiatry Res Neuroimaging. 2019 May 30;287:60-62. doi: 10.1016/j.pscychresns.2019.04.003. Epub 2019 Apr 11.

PMID:
30991249
22.

Are Placebo-Controlled, Relapse Prevention Trials in Schizophrenia Research Still Necessary or Ethical?

Lawrence RE, Appelbaum PS, Lieberman JA.

JAMA Psychiatry. 2019 Jul 1;76(7):673-674. doi: 10.1001/jamapsychiatry.2019.0275. No abstract available.

PMID:
30969331
23.

Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia.

Bitter I, Lieberman JA, Gaudoux F, Sokoloff P, Groc M, Chavda R, Delsol C, Barthe L, Brunner V, Fabre C, Fagard M, Montagne A, Tonner F.

Neuropsychopharmacology. 2019 Oct;44(11):1917-1924. doi: 10.1038/s41386-019-0355-2. Epub 2019 Mar 1.

PMID:
30822774
24.

Herbert D. Kleber.

Levin FR, Lieberman JA, Pardes H.

Neuropsychopharmacology. 2019 Apr;44(5):1007. doi: 10.1038/s41386-019-0318-7. Epub 2019 Feb 4. No abstract available.

25.

Prevalence and phenomenology of violent ideation and behavior among 200 young people at clinical high-risk for psychosis: an emerging model of violence and psychotic illness.

Brucato G, Appelbaum PS, Masucci MD, Rolin S, Wall MM, Levin M, Altschuler R, First MB, Lieberman JA, Girgis RR.

Neuropsychopharmacology. 2019 Apr;44(5):907-914. doi: 10.1038/s41386-018-0304-5. Epub 2018 Dec 27.

26.

Identification and Management of Cardiometabolic Risk after Spinal Cord Injury: Clinical Practice Guideline for Health Care Providers.

Nash MS, Groah SL, Gater DR Jr, Dyson-Hudson TA, Lieberman JA, Myers J, Sabharwal S, Taylor AJ; Consortium for Spinal Cord Medicine.

Top Spinal Cord Inj Rehabil. 2018 Fall;24(4):379-423. doi: 10.1310/sci2404-379. No abstract available.

27.

AR101 Oral Immunotherapy for Peanut Allergy.

PALISADE Group of Clinical Investigators, Vickery BP, Vereda A, Casale TB, Beyer K, du Toit G, Hourihane JO, Jones SM, Shreffler WG, Marcantonio A, Zawadzki R, Sher L, Carr WW, Fineman S, Greos L, Rachid R, Ibáñez MD, Tilles S, Assa’ad AH, Nilsson C, Rupp N, Welch MJ, Sussman G, Chinthrajah S, Blumchen K, Sher E, Spergel JM, Leickly FE, Zielen S, Wang J, Sanders GM, Wood RA, Cheema A, Bindslev-Jensen C, Leonard S, Kachru R, Johnston DT, Hampel FC Jr, Kim EH, Anagnostou A, Pongracic JA, Ben-Shoshan M, Sharma HP, Stillerman A, Windom HH, Yang WH, Muraro A, Zubeldia JM, Sharma V, Dorsey MJ, Chong HJ, Ohayon J, Bird JA, Carr TF, Siri D, Fernández-Rivas M, Jeong DK, Fleischer DM, Lieberman JA, Dubois AEJ, Tsoumani M, Ciaccio CE, Portnoy JM, Mansfield LE, Fritz SB, Lanser BJ, Matz J, Oude Elberink HNG, Varshney P, Dilly SG, Adelman DC, Burks AW.

N Engl J Med. 2018 Nov 22;379(21):1991-2001. doi: 10.1056/NEJMoa1812856. Epub 2018 Nov 18.

PMID:
30449234
28.

Severity of peanut allergy and the unmet gaps in care: a call to action.

Lieberman JA.

Am J Manag Care. 2018 Oct;24(19 Suppl):S412-S418. Review.

29.

Investigation of the HSPG2 Gene in Tardive Dyskinesia - New Data and Meta-Analysis.

Zai CC, Lee FH, Tiwari AK, Lu JY, de Luca V, Maes MS, Herbert D, Shahmirian A, Cheema SY, Zai GC, Atukuri A, Sherman M, Shaikh SA, Tampakeras M, Freeman N, King N, Müller DJ, Greenbaum L, Lerer B, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Remington G, Kennedy JL.

Front Pharmacol. 2018 Sep 18;9:974. doi: 10.3389/fphar.2018.00974. eCollection 2018.

30.

Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia.

Lu JY, Tiwari AK, Zai GC, Rastogi A, Shaikh SA, Müller DJ, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Remington G, Wong AHC, Kennedy JL, Zai CC.

Neurosci Lett. 2018 Nov 1;686:17-22. doi: 10.1016/j.neulet.2018.08.007. Epub 2018 Aug 15.

PMID:
30118782
31.

The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review.

Girgis RR, Zoghbi AW, Javitt DC, Lieberman JA.

J Psychiatr Res. 2019 Jan;108:57-83. doi: 10.1016/j.jpsychires.2018.07.006. Epub 2018 Jul 21. Review.

PMID:
30055853
32.

The reliability of motor evoked potentials to predict dorsiflexion injuries during lumbosacral deformity surgery: importance of multiple myotomal monitoring.

Lieberman JA, Lyon R, Jasiukaitis P, Berven SH, Burch S, Feiner J.

Spine J. 2019 Mar;19(3):377-385. doi: 10.1016/j.spinee.2018.07.006. Epub 2018 Jul 17.

PMID:
30025994
33.

Psychotic Disorders.

Lieberman JA, First MB.

N Engl J Med. 2018 Jul 19;379(3):270-280. doi: 10.1056/NEJMra1801490. Review. No abstract available.

PMID:
30021088
34.

A predictive model for conversion to psychosis in clinical high-risk patients.

Ciarleglio AJ, Brucato G, Masucci MD, Altschuler R, Colibazzi T, Corcoran CM, Crump FM, Horga G, Lehembre-Shiah E, Leong W, Schobel SA, Wall MM, Yang LH, Lieberman JA, Girgis RR.

Psychol Med. 2019 May;49(7):1128-1137. doi: 10.1017/S003329171800171X. Epub 2018 Jun 28.

PMID:
29950184
35.

Are there different subtypes of eosinophilic esophagitis?

Lieberman JA.

Ann Allergy Asthma Immunol. 2018 Aug;121(2):143-144. doi: 10.1016/j.anai.2018.05.023. Epub 2018 Jun 1. No abstract available.

PMID:
29860052
36.

Disease modifying effects of antipsychotic drugs in schizophrenia: a clinical and neurobiological perspective.

Lieberman JA.

World Psychiatry. 2018 Jun;17(2):163-165. doi: 10.1002/wps.20543. No abstract available.

37.

A randomized, double-blinded, placebo-controlled study of the use of viscous oral cromolyn sodium for the treatment of eosinophilic esophagitis.

Lieberman JA, Zhang J, Whitworth J, Cavender C.

Ann Allergy Asthma Immunol. 2018 May;120(5):527-531. doi: 10.1016/j.anai.2018.03.006. Epub 2018 Mar 12.

PMID:
29544738
38.

Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo.

Ballon JS, Pajvani UB, Mayer LE, Freyberg Z, Freyberg R, Contreras I, Rosenbaum M, Leibel RL, Lieberman JA.

J Psychopharmacol. 2018 May;32(5):533-540. doi: 10.1177/0269881118754708. Epub 2018 Feb 15.

39.

The environment and food allergy.

Lieberman JA, Greenhawt M, Nowak-Wegrzyn A.

Ann Allergy Asthma Immunol. 2018 May;120(5):455-457. doi: 10.1016/j.anai.2018.01.010. Epub 2018 Feb 2. Review. No abstract available.

PMID:
29410214
40.

Understanding fibrosis in eosinophilic esophagitis: Are we there yet?

Armbruster-Lee J, Cavender CP, Lieberman JA, Samarasinghe AE.

J Leukoc Biol. 2018 Jul;104(1):31-40. doi: 10.1002/JLB.5MR1017-395R. Epub 2018 Jan 29. Review.

PMID:
29377264
41.

Identical twins with XLA requiring differing amounts of 20% subcutaneous immunoglobulin secondary to protein-losing enteropathy.

Lan J, Eshun J, Lieberman JA.

J Allergy Clin Immunol Pract. 2018 May - Jun;6(3):1073-1074. doi: 10.1016/j.jaip.2017.11.030. Epub 2018 Jan 12. No abstract available.

PMID:
29339123
42.

Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and intervention.

Lieberman JA, Girgis RR, Brucato G, Moore H, Provenzano F, Kegeles L, Javitt D, Kantrowitz J, Wall MM, Corcoran CM, Schobel SA, Small SA.

Mol Psychiatry. 2018 Aug;23(8):1764-1772. doi: 10.1038/mp.2017.249. Epub 2018 Jan 9. Review.

43.

Allergists' opinions on anaphylaxis and epinephrine administration-a case-based survey.

Lieberman JA, Lieberman P, Wang J.

J Allergy Clin Immunol Pract. 2018 May - Jun;6(3):1075-1077.e1. doi: 10.1016/j.jaip.2017.11.031. Epub 2018 Jan 4. No abstract available.

PMID:
29306683
44.

Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine.

Girardin FR, Poncet A, Perrier A, Vernaz N, Pletscher M, F Samer C, Lieberman JA, Villard J.

Pharmacogenomics J. 2019 Apr;19(2):211-218. doi: 10.1038/s41397-017-0004-2. Epub 2018 Jan 3.

45.

Psychiatrists Diagnosing the President - Moral Imperative or Ethical Violation?

Lieberman JA.

N Engl J Med. 2018 Feb 1;378(5):483-484. doi: 10.1056/NEJMc1716751. Epub 2017 Dec 27. No abstract available.

PMID:
29281477
46.

Nutrition education for cardiovascular disease prevention in individuals with spinal cord injuries: study protocol for a randomized controlled trial.

Lieberman JA, McClelland JW, Goff DC Jr, Racine E, Dulin MF, Bauman WA, Niemeier J, Hirsch MA, Norton HJ, Moore CG.

Trials. 2017 Dec 4;18(1):584. doi: 10.1186/s13063-017-2263-2.

47.

Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial.

Javitt DC, Carter CS, Krystal JH, Kantrowitz JT, Girgis RR, Kegeles LS, Ragland JD, Maddock RJ, Lesh TA, Tanase C, Corlett PR, Rothman DL, Mason G, Qiu M, Robinson J, Potter WZ, Carlson M, Wall MM, Choo TH, Grinband J, Lieberman JA.

JAMA Psychiatry. 2018 Jan 1;75(1):11-19. doi: 10.1001/jamapsychiatry.2017.3572.

48.

Unproven Diagnostic Tests for Food Allergy.

Hammond C, Lieberman JA.

Immunol Allergy Clin North Am. 2018 Feb;38(1):153-163. doi: 10.1016/j.iac.2017.09.011. Review.

PMID:
29132671
49.

Correction to: Changes in transcranial motor evoked potentials during hemorrhage are associated with increased serum propofol concentrations.

Lieberman JA, Feiner J, Rollins M, Lyon R, Jasiukaitis P.

J Clin Monit Comput. 2018 Jun;32(3):581. doi: 10.1007/s10877-017-0075-2.

PMID:
29119425
50.

Eliminating the Glass Ceiling in Academic Psychiatry.

Lieberman JA, Ehrhardt AA, Simpson HB, Arbuckle MR, Fyer AJ, Essock SM.

Acad Psychiatry. 2018 Aug;42(4):523-528. doi: 10.1007/s40596-017-0810-5. Epub 2017 Nov 6. No abstract available.

Supplemental Content

Loading ...
Support Center